Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

87 ArticlesPharmaceuticals

9 / 9

Sun-Baxy Deal Dinged For Insider Trading

The SunPharma-Ranbaxy deal has hit a little snag. The Andhra Pradesh High Court has temporarily stalled the merger, asking SEBI and stock exchanges not to ...

Apr 30, 2014

Strides Up 12% on FDA Approval, Portfolio Gains

This is a Capital Mind Premium post, sent on April 26, 2014. Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor ...

Apr 28, 2014

Sun Pharma and Ranbaxy to Merge, Create Giant Pharma Co

The big news of the week was about a mega-merger of two of India’s largest pharma companies, Sun Pharma and Ranbaxy. ...

Apr 09, 2014

Premium: Strides Arcolab Declares Rs. 500 Dividend, a 56% Yield – Good Deal?

This is an archive for Capital Mind Premium subscribers, sent on 14th December 2013. The Case of Strides Arcolab Strides Arcolab recently sold it’s Agila ...

Dec 15, 2013

The Can of Worms at Ranbaxy

Fortune magazine has a long and detailed story about Ranbaxy and the reason for its $500 million settlement with the FDA. But in Gurgaon, as Thakur’s ...

May 23, 2013

On Vacation: Stepping Back in Time

I’m on vacation, in Goa for a few days so posting will be slow this week. Goa is my favourite place to holiday. And even after two kids, the costs of a ...

Apr 03, 2013

Biggest Losers: Marksans pharma

I’ve invested in stocks, on and off, for a while now and while I tend to talk about some of the stocks I’ve liked and have done well, let me tell ...

May 18, 2007

Join Capitalmind Premium

Starts at ₹1,999/mo

Get access to our equity, fixed income, macro and personal finance research, model equity and fixed-income portfolios, exclusive apps, tutorials, and member community.